Matteo Foschi Shares Review on Ischemic Stroke Despite Appropriate Oral Anticoagulation
Matteo Foschi, Neurologist at Azienda USL della Romagna, shared on LinkedIn:
”Our systematic review and meta-analysis on ischemic stroke despite appropriate oral anticoagulation is now published in Neurological Sciences Springer Nature
Across 10,624 patients, we found:
• a high burden of vascular risk factors,
• moderate stroke severity,
• and better 90-day functional outcomes with DOACs vs VKAs (60.4% vs 35.7%).
Despite guideline-recommended OAC, stroke still occurs — and major knowledge gaps persist regarding mechanisms and long-term prognosis.
This is exactly the space the ASPERA Registry is designed to fill, and the first ASPERA papers will emerge soon.”
Read the full article here.
Article: Clinical characteristics and outcomes of ischemic stroke despite appropriate oral anticoagulation for atrial fibrillation: A systematic review and meta-analysis of real-world studies
Authors: Francesca Gabriele, Federico De Santis, Maria Grazia Vittorini, Lucio D’Anna, Giovanni Merlino, Francesco Bax, Raffaele Ornello, Simona Sacco, Matteo Foschi

Stay updated on all scientific advances with Hemostasis Today.
-
Feb 23, 2026, 13:53Rare Diseases, Plasma-Derived Medicines and the Elephant in the Room – Part 1
-
Feb 23, 2026, 13:02Deepak Yadav: What 2025 Evidence Tells Us About Stroke Care
-
Feb 23, 2026, 12:55Radoslaw Kaczmarek: Will AAV Gene Therapy for Hemophilia Trigger Tumorigenesis?
-
Feb 23, 2026, 12:46Heghine Khachatryan: More Granular Risk Stratification Framework for PE from The New 2026 AHA/ACC Guideline
-
Feb 23, 2026, 12:37Reza Shojaei: EU’s Critical Medicines Act and Plasma Resilience
-
Feb 23, 2026, 12:32Anirban Sen Gupta: Emily Mihalko Highlights PlateChek at MTEC
-
Feb 23, 2026, 12:25Ryan Williams: Excellent Highlights on The Heterogeneity of PRP Preparation
-
Feb 23, 2026, 12:10Peter Libby: hsCRP May Select Patients Who Can Benefit From Statins or Anti-inflammatory Therapy
-
Feb 23, 2026, 12:02Marios Georgakis: An Unprecedented for An Antithrombotic Therapy from OCEANIC-STROKE Trial